The former executive director of the European Medicines Agency, Thomas Lonngren, is taking on an advisory role with consultants NDA Group and specifically at the latter's new European regulatory and market access business.
The NDA Group, which is based in Germany, Sweden and the UK and was founded in 1997, has launched a new regulatory and market access business which it says aims to slash rising costs and address the challenges of drug regulation and reimbursement. Dr Lonngren, who has just completed his 10-year spell at the helm of EMA, will advise NDA Advisory Services, which will be headquartered in the UK.
He said “I’ve recognised for a long time that the whole area of market access needs new ideas and a new vision". As such, he plans to "further develop my ideas surrounding international regulatory strategies, coupled with pushing for a joined-up approach to Health Technology Assessment, to enable the best medicines to reach needy patients as efficiently as possible".
The NDA Group noted that it already consults more than 400 drug development firms, including 90% of the world’s top 20 pharmaceutical companies.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.